Bionano Genomics Files 8-K for Financial Statements
Ticker: BNGO · Form: 8-K · Filed: Apr 8, 2024 · CIK: 1411690
| Field | Detail |
|---|---|
| Company | Bionano Genomics, Inc. (BNGO) |
| Form Type | 8-K |
| Filed Date | Apr 8, 2024 |
| Risk Level | low |
| Pages | 2 |
| Reading Time | 2 min |
| Key Dollar Amounts | $0.0001 |
| Sentiment | neutral |
Sentiment: neutral
Topics: financial-reporting, 8-k
Related Tickers: BNGO
TL;DR
Bionano Genomics dropped an 8-K with financial updates - check it out.
AI Summary
On April 8, 2024, Bionano Genomics, Inc. filed an 8-K report. The filing primarily concerns financial statements and exhibits, indicating updates or disclosures related to the company's financial status and operations. No specific material events or transactions were detailed in the provided excerpt.
Why It Matters
This filing provides an update on Bionano Genomics' financial reporting, which is crucial for investors to assess the company's financial health and performance.
Risk Assessment
Risk Level: low — The filing is a routine 8-K for financial statements and exhibits, not indicating any immediate material adverse events.
Key Players & Entities
- Bionano Genomics, Inc. (company) — Registrant
- April 8, 2024 (date) — Date of earliest event reported
- Delaware (jurisdiction) — State of Incorporation
- 001-38613 (identifier) — Commission File Number
- 26-1756290 (identifier) — IRS Employer Identification No.
- 9540 Towne Centre Drive, Suite 100 (address) — Principal Executive Offices
- San Diego, California 92121 (address) — Principal Executive Offices
FAQ
What specific financial statements or exhibits are being filed with this 8-K?
The provided excerpt states the filing concerns 'Financial Statements and Exhibits' but does not list the specific documents included.
What is the significance of the 'Other Events' item information?
The 'Other Events' item information suggests that there may be other material events to report, though none are detailed in this excerpt.
When was Bionano Genomics, Inc. incorporated?
Bionano Genomics, Inc. was incorporated in Delaware.
What is the principal executive office address for Bionano Genomics, Inc.?
The principal executive office is located at 9540 Towne Centre Drive, Suite 100, San Diego, California 92121.
Is this filing related to a specific material event or a routine financial update?
The filing is categorized under 'Other Events' and 'Financial Statements and Exhibits,' suggesting it may include routine financial updates and potentially other undisclosed events.
Filing Stats: 542 words · 2 min read · ~2 pages · Grade level 10 · Accepted 2024-04-08 16:56:24
Key Financial Figures
- $0.0001 — ange on which registered Common Stock, $0.0001 par value per share BNGO The Nasdaq
Filing Documents
- ny20026243x2_8k.htm (8-K) — 27KB
- ny20026243x2_ex5-1.htm (EX-5.1) — 18KB
- image01.jpg (GRAPHIC) — 10KB
- 0001140361-24-018645.txt ( ) — 231KB
- bngo-20240408.xsd (EX-101.SCH) — 4KB
- bngo-20240408_def.xml (EX-101.DEF) — 17KB
- bngo-20240408_lab.xml (EX-101.LAB) — 25KB
- bngo-20240408_pre.xml (EX-101.PRE) — 19KB
- ny20026243x2_8k_htm.xml (XML) — 5KB
01
Item 8.01 Other Events. On April 8, 2024, Bionano Genomics, Inc. (the "Company") filed a prospectus supplement (the "Prospectus Supplement") to its effective registration statement on Form S-3 (File No. 333-270459) (the "Registration Statement") filed with the U.S. Securities and Exchange Commission, under the Securities Act of 1933, as amended, with respect to the sale and issuance in a registered direct offering by the Company of (i) 6,536,682 shares (the "Shares") of the Company's common stock, par value $0.0001 per share (the "Common Stock"), (ii) pre-funded warrants to purchase 2,196,944 shares of Common Stock, and (iii) warrants to purchase 8,733,626 shares of Common Stock (the "Warrant Shares"). In connection with the filing of the Prospectus Supplement, the Company is filing a legal opinion of its counsel, Cooley LLP, regarding the validity of the Shares and the Warrant Shares being registered, which opinion is attached as Exhibit 5.1 to this Current Report on Form 8-K.
Financial Statements and Exhibits
Financial Statements and Exhibits. (d) Exhibits Exhibit Description 5.1 Opinion of Cooley LLP 104 Inline XBRL for the cover page of this Current Report on Form 8-K.
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Date: April 8, 2024 Bionano Genomics, Inc. By: /s/ R. Erik Holmlin, Ph.D. R. Erik Holmlin, Ph.D. President and Chief Executive Officer (Principal Executive Officer)